232 related articles for article (PubMed ID: 17229916)
21. A novel mutation in the complement regulator clusterin in recurrent hemolytic uremic syndrome.
Ståhl AL; Kristoffersson A; Olin AI; Olsson ML; Roodhooft AM; Proesmans W; Karpman D
Mol Immunol; 2009 Jul; 46(11-12):2236-43. PubMed ID: 19446882
[TBL] [Abstract][Full Text] [Related]
22. Inherited dysregulation of the complement system.
Goodship T
Bull Mem Acad R Med Belg; 2004; 159(Pt 2):195-8. PubMed ID: 15615093
[TBL] [Abstract][Full Text] [Related]
23. Comparison of surface recognition and C3b binding properties of mouse and human complement factor H.
Cheng ZZ; Hellwage J; Seeberger H; Zipfel PF; Meri S; Jokiranta TS
Mol Immunol; 2006 Mar; 43(7):972-9. PubMed ID: 16023208
[TBL] [Abstract][Full Text] [Related]
24. Atypical haemolytic uraemic syndrome.
Kavanagh D; Goodship TH; Richards A
Br Med Bull; 2006; 77-78():5-22. PubMed ID: 16968692
[TBL] [Abstract][Full Text] [Related]
25. The endothelial glycocalyx as a potential modifier of the hemolytic uremic syndrome.
Boels MG; Lee DH; van den Berg BM; Dane MJ; van der Vlag J; Rabelink TJ
Eur J Intern Med; 2013 Sep; 24(6):503-9. PubMed ID: 23357408
[TBL] [Abstract][Full Text] [Related]
26. Phenotypic expression of factor H mutations in patients with atypical hemolytic uremic syndrome.
Vaziri-Sani F; Holmberg L; Sjöholm AG; Kristoffersson AC; Manea M; Frémeaux-Bacchi V; Fehrman-Ekholm I; Raafat R; Karpman D
Kidney Int; 2006 Mar; 69(6):981-8. PubMed ID: 16528247
[TBL] [Abstract][Full Text] [Related]
27. Complement and diseases: defective alternative pathway control results in kidney and eye diseases.
Zipfel PF; Heinen S; Józsi M; Skerka C
Mol Immunol; 2006 Jan; 43(1-2):97-106. PubMed ID: 16026839
[TBL] [Abstract][Full Text] [Related]
28. The autoimmune disease DEAP-hemolytic uremic syndrome.
Skerka C; Zipfel PF; Müller D; Micklisch S; Riedl M; Zimmerhackl LB; Hofer J
Semin Thromb Hemost; 2010 Sep; 36(6):625-32. PubMed ID: 20865639
[TBL] [Abstract][Full Text] [Related]
29. Shiga toxin enhances functional tissue factor on human glomerular endothelial cells: implications for the pathophysiology of hemolytic uremic syndrome.
Nestoridi E; Tsukurov O; Kushak RI; Ingelfinger JR; Grabowski EF
J Thromb Haemost; 2005 Apr; 3(4):752-62. PubMed ID: 15842359
[TBL] [Abstract][Full Text] [Related]
30. Hemolytic uremic syndrome: an example of insufficient complement regulation on self-tissue.
Atkinson JP; Liszewski MK; Richards A; Kavanagh D; Moulton EA
Ann N Y Acad Sci; 2005 Nov; 1056():144-52. PubMed ID: 16387683
[TBL] [Abstract][Full Text] [Related]
31. Mutations in proteins of the alternative pathway of complement and the pathogenesis of atypical hemolytic uremic syndrome.
Abarrategui-Garrido C; Melgosa M; Peña-Carrión A; de Jorge EG; de Córdoba SR; López-Trascasa M; Sánchez-Corral P
Am J Kidney Dis; 2008 Jul; 52(1):171-80. PubMed ID: 18423815
[TBL] [Abstract][Full Text] [Related]
32. Crystallographic determination of the disease-associated T1184R variant of complement regulator factor H.
Morgan HP; Jiang J; Herbert AP; Kavanagh D; Uhrin D; Barlow PN; Hannan JP
Acta Crystallogr D Biol Crystallogr; 2011 Jul; 67(Pt 7):593-600. PubMed ID: 21697597
[TBL] [Abstract][Full Text] [Related]
33. Update on evaluating complement in hemolytic uremic syndrome.
Kavanagh D; Goodship TH
Curr Opin Nephrol Hypertens; 2007 Nov; 16(6):565-71. PubMed ID: 18089972
[TBL] [Abstract][Full Text] [Related]
34. Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome.
Orth D; Khan AB; Naim A; Grif K; Brockmeyer J; Karch H; Joannidis M; Clark SJ; Day AJ; Fidanzi S; Stoiber H; Dierich MP; Zimmerhackl LB; Würzner R
J Immunol; 2009 May; 182(10):6394-400. PubMed ID: 19414792
[TBL] [Abstract][Full Text] [Related]
35. Complement dysfunction in hemolytic uremic syndrome.
Zipfel PF; Skerka C
Curr Opin Rheumatol; 2006 Sep; 18(5):548-55. PubMed ID: 16896298
[TBL] [Abstract][Full Text] [Related]
36. [From gene to disease; the haemolytic uraemic syndrome can be caused by mutations in regulating factors of the alternative route of the complement system].
Geelen JM; Klasen IS; van den Heuvel LP; Monnens LA
Ned Tijdschr Geneeskd; 2007 Jan; 151(3):185-8. PubMed ID: 17288344
[TBL] [Abstract][Full Text] [Related]
37. Anti-factor H autoantibody-associated hemolytic uremic syndrome: review of literature of the autoimmune form of HUS.
Dragon-Durey MA; Blanc C; Garnier A; Hofer J; Sethi SK; Zimmerhackl LB
Semin Thromb Hemost; 2010 Sep; 36(6):633-40. PubMed ID: 20865640
[TBL] [Abstract][Full Text] [Related]
38. A user's guide to the interactive Web database of factor H-associated hemolytic uremic syndrome.
Saunders RE; Perkins SJ
Semin Thromb Hemost; 2006 Mar; 32(2):160-8. PubMed ID: 16575691
[TBL] [Abstract][Full Text] [Related]
39. Atypical hemolytic uremic syndrome-associated variants and autoantibodies impair binding of factor h and factor h-related protein 1 to pentraxin 3.
Kopp A; Strobel S; Tortajada A; Rodríguez de Córdoba S; Sánchez-Corral P; Prohászka Z; López-Trascasa M; Józsi M
J Immunol; 2012 Aug; 189(4):1858-67. PubMed ID: 22786770
[TBL] [Abstract][Full Text] [Related]
40. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome.
Sellier-Leclerc AL; Fremeaux-Bacchi V; Dragon-Durey MA; Macher MA; Niaudet P; Guest G; Boudailliez B; Bouissou F; Deschenes G; Gie S; Tsimaratos M; Fischbach M; Morin D; Nivet H; Alberti C; Loirat C;
J Am Soc Nephrol; 2007 Aug; 18(8):2392-400. PubMed ID: 17599974
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
